What is HC Wainwright's Estimate for MIST FY2028 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - HC Wainwright decreased their FY2028 earnings per share estimates for Milestone Pharmaceuticals in a report released on Tuesday, July 15th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.16 per share for the year, down from their prior estimate of $0.19. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' FY2029 earnings at $0.58 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12).

Several other research firms have also recently weighed in on MIST. TD Cowen cut Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Securities cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, Cowen cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $7.00.

Milestone Pharmaceuticals Stock Down 4.2%

NASDAQ:MIST traded down $0.07 during trading hours on Wednesday, reaching $1.58. 1,735,891 shares of the company traded hands, compared to its average volume of 1,130,828. The business's 50-day moving average price is $1.68 and its two-hundred day moving average price is $1.67. The stock has a market capitalization of $84.47 million, a P/E ratio of -2.03 and a beta of 0.96. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.75. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 4.06.

Institutional Trading of Milestone Pharmaceuticals

Large investors have recently modified their holdings of the company. Jones Financial Companies Lllp grew its holdings in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares during the period. National Bank of Canada FI lifted its position in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after buying an additional 11,600 shares in the last quarter. Bay Rivers Group purchased a new stake in shares of Milestone Pharmaceuticals in the second quarter worth about $28,000. XTX Topco Ltd lifted its position in shares of Milestone Pharmaceuticals by 52.7% in the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after buying an additional 17,950 shares in the last quarter. Finally, Northern Trust Corp raised its position in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after purchasing an additional 30,772 shares during the period. Institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.